GRTX - Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment
- Galera Therapeutics ( NASDAQ: GRTX ) stock has lost 7.8% to $1.42 in Wednesday morning trade after announcing phase 1 data for its molecule rucosopasem in combination with stereotactic body radiation therapy to treat patients with non-small cell lung cancer.
- The results from the early-stage phase of the GRECO-1 trial showed that rucosopasem was safe and well tolerated in a group of seven patients, GRTX said.
- The results also showed early indications of anti-cancer activity and pulmonary function preservation.
- GRTX said enrollment is now ongoing in the placebo-controlled phase 2 stage of the trial.
For further details see:
Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment